MCW Cancer Center logo

Funding and Grants

Current Funding Opportunities

National Cancer Institute (NCI)

Open AllClose All
  Cancer Prevention Fellowship Program (CPFP) (Deadline: 8/25/16)

Cancer Prevention Fellowship Program (CPFP)

The NCI Cancer Prevention Fellowship Program provides postdoctoral training opportunities in cancer prevention and control. Under the shared guidance of an individual NCI preceptor and the CPFP scientific staff, fellows will develop original research projects in cancer prevention and control. Collaboration with investigators throughout the NCI is encouraged. Research opportunities include, but are not limited to:

  • biomarker development
  • chemoprevention studies
  • clinical cancer prevention research
  • effectiveness and outcomes research
  • epidemiology (clinical, environmental, genetic, molecular, nutritional)
  • ethics and evidence-based decision making (theoretical and practical studies)
  • health disparities and special populations
  • laboratory-based research (chemoprevention, molecular biology and genetics, nutritional science)
  • screening and early detection,
  • social and behavioral research, and
  • statistical methodology (biometry and bioinformatics)

Applications due August 25, 2016

  Biological Comparisons in Patient-Derived Models of Cancer (U01) (Deadline: 9/14/16)

Biological Comparisons in Patient-Derived Models of Cancer (U01)

The purpose of this FOA is to encourage applications wherein similarities and differences in the underlying biological mechanisms that drive cancer phenotype and response to perturbations between two or more patient-derived models of cancer originating from a common patient sample are delineated and compared.

Applications due September 14, 2016

  Cancer Target Discovery and Development Network (U01) (Deadline: 10/3/16)

Cancer Target Discovery and Development Network (U01)

This Funding Opportunity Announcement (FOA) will continue to support the program "Cancer Target Discovery and Development” (CTD^2, pronounced cee-tee-dee-squared).  CTD^2 is focused on efforts that advance cancer research by bridging the knowledge gap between the rapidly increasing volumes of new data generated by comprehensive molecular characterizations of many cancer types and studies of the underlying etiology of cancer development, progression, and/or metastasis.

The primary purpose of the CTD^2 program is to advance our understanding of cancer etiology, mechanisms and treatment through:

  • Improving the understanding of how mutations in cancer genes affect the downstream functions (e.g., gain-of-function, loss-of-function, or neomorphic function) within the protein and cellular pathway(s);
     
  • Searching for new molecular targets with the goal to overcome innate and/or acquired resistance to therapies, particularly clinical resistance related to inter- and intra- tumor heterogeneity; and
     
  • Developing efficient strategies to identify appropriate multiple targets and optimal combination of perturbagens (chemical or biological; immunotherapeutics being a prime example of the latter) with the potential to eliminate all cancer cells, despite their clonal heterogeneity.

This FOA solicits applications for research projects  advancing the goals outlined above. The proposed projects should use a combination of state-of-the-art high throughput informatic and experimental approaches to address at a minimum two of these three research areas: (1)  characterization and validation of novel cancer targets; (2) identification of molecular markers that can meaningfully predict responses or resistance to anticancer therapies; and (3) development of perturbagens that can affect the proposed targets of cancer treatment.

Applications due October 3, 2016

  Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01) (Deadline: 10/5/16)

Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01)

This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.

Applications due October 5, 2016

  Building Interdisciplinary Research Careers in Women's Health (K12) (Deadline: 10/6/16)

Building Interdisciplinary Research Careers in Women's Health (K12)

The NIH Office of Research on Women's Health (ORWH) and participating NIH Institutes and Centers invite institutional career development award applications for Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Career Development Programs, hereafter termed "Programs". Programs will support mentored research career development of junior faculty members, known as BIRCWH Scholars, who have recently completed clinical training or postdoctoral fellowships, and who will be engaged in interdisciplinary basic, translational, behavioral, clinical, and/or health services research relevant to women's health, and, where appropriate, the use of both sexes to better understand the influence of sex as a variable on health and disease.

Applications due October 6, 2016

  Assay Validation For High Quality Markers For NCI-Supported Clinical Trials (UH2/UH3) (Deadline: 10/7/16)

Assay Validation For High Quality Markers For NCI-Supported Clinical Trials (UH2/UH3)

The purpose of this Funding Opportunity Announcement (FOA) is to improve the development and validation of molecular diagnostics for the treatment, control, or prevention of cancer. This FOA includes, but is not limited to, the validation of prognostic, predictive or response markers for treatment and markers for cancer control or prevention trials. Applicants should have an assay that works in human samples and whose importance is well justified for development into a clinical assay. The UH2 phase of this FOA supports analytical validation of assays for these markers that must be achieved within two years before an assay may undergo clinical validation. The UH3 phase of this FOA supports the clinical validation of established assays for up to three years using specimens from retrospective or prospective studies from NCI-supported or other clinical trials. In both the UH2 and UH3 phases, clinical laboratory staff, technical and other needs must be an integral part of the application. Assays proposed for this FOA may be used to validate existing assays for use in other cancer clinical trials, observational studies or populations. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among scientific investigators, clinicians, statisticians and clinical laboratory scientists and staff.

This FOA is not intended to support trials that assess the clinical utility of a marker/assay but is intended to develop assays to the point where their clinical utility could be assessed in other trials. Investigators responding to this FOA must address both UH2 and UH3 phases.

Applications due October 7, 2016

  Assay Validation For High Quality Markers For NCI-Supported Clinical Trials (UH3) (Deadline: 10/7/16)

Assay Validation For High Quality Markers For NCI-Supported Clinical Trials (UH3)

The purpose of this Funding Opportunity Announcement (FOA) is to improve the development and validation of molecular diagnostics for the treatment, control, or prevention of cancer. This FOA includes, but is not limited to, the validation of prognostic, predictive or response markers for treatment and markers for cancer control or prevention trials. Applicants to this FOA must have an assay whose performance has been analytically validated within specimens similar to those for the intended clinical use of the assay and marker. The UH3 mechanism supports the clinical validation of established assays for up to three years using specimens from retrospective or prospective studies from NCI-supported or other clinical trials. Assays proposed for this FOA may be used to validate existing assays for use in other trials, observational studies or populations. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among scientific investigators, clinicians, statisticians and clinical laboratory scientists and staff. Clinical laboratory staff, technical and other needs must be an integral part of the application.

This FOA is not intended to support trials that assess the clinical utility of a marker/assay but is intended to develop assays to the point where their clinical utility could be assessed in other trials.

Applications due October 7, 2016

  Intervening With Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01) (Deadline: 10/7/16)

Intervening With Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01)

This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes.

Applications due October 7, 2016

  Intervening With Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R21) (Deadline: 10/7/16)

Intervening With Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R21)

This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes.

Applications due October 7, 2016

  Innovative Approaches to Studying Cancer Communication in the New Media Environment (R01) (Deadline: 10/11/16)

Innovative Approaches to Studying Cancer Communication in the New Media Environment (R01)

This Funding Opportunity Announcement (FOA) invites applications that seek to apply one or more innovative methodologies in communication research across the cancer control continuum, from prevention, early detection, diagnosis, treatment, and survivorship, to end of life. Applications to this FOA should utilize one or more of the following analytic approaches, methods, and data sources, including but not limited to social media data mining, Natural Language Processing (NLP) techniques, online social network analysis, crowdsourcing research tools (e.g., mTurk), online search data, Ecological Momentary Assessment, neuroscience and biobehavioral approaches to communication, and geographic information systems.  Studies should assess outcomes related to cancer prevention and control (e.g., knowledge, attitudes, beliefs, perceived risk, decision making in screening and treatment, information inequalities, social support, shared decision making, persuasion, caregiving, behavioral intentions, preventive behaviors, and policy support, among others).

Earliest submission date September 11, 2016

Applications due October 11, 2016

  Innovative Approaches to Studying Cancer Communication in the New Media Environment (R21) (Deadline: 10/11/16)

Innovative Approaches to Studying Cancer Communication in the New Media Environment (R21)

This Funding Opportunity Announcement (FOA) invites applications that seek to apply one or more innovative methodologies in communication research across the cancer control continuum, from prevention, early detection, diagnosis, treatment, and survivorship, to end of life. Applications to this FOA should utilize one or more of the following analytic approaches, methods, and data sources, including but not limited to social media data mining, Natural Language Processing (NLP) techniques, online social network analysis, crowdsourcing research tools (e.g., mTurk), online search data, Ecological Momentary Assessment, neuroscience and biobehavioral approaches to communication, and geographic information systems. Studies should assess outcomes related to cancer prevention and control (e.g., knowledge, attitudes, beliefs, perceived risk, decision making in screening and treatment, information inequalities, social support, shared decision making, persuasion, caregiving, behavioral intentions, preventive behaviors, and policy support, among others).

Earliest submission date September 11, 2016

Applications due October 11, 2016

  NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08) (Deadline: 10/12/16)

NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08)

The purpose of the NCI Mentored Clinical Scientist Career Development Award (K08) program is to prepare individuals for careers that have a significant impact on the health-related research needs of the nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.

The NCI-sponsored K08 award is specifically designed to promote career development of clinical scientists from diverse backgrounds that have been shown to be underrepresented in health-related science and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career development and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared to compete for research project grants (e.g. R03, R21, or R01) funding.

Applications due October 12, 2016

  NCI Mentored Patient-Oriented Research Career Development Award to Promote Diversity (K23) (Deadline: 10/12/16)

NCI Mentored Patient-Oriented Research Career Development Award to Promote Diversity (K23)

The NCI's Diversity Training Branch (DTB) and the Center to Reduce Cancer Health Disparities (CRCHD) announce the availability of the "Mentored Patient-Oriented Research Award to Promote Diversity" for career development of individuals with a health professional doctoral degree from groups currently underrepresented on a national level in the biomedical, clinical, behavioral, and social sciences. The NCI recognizes a unique and compelling need to promote diversity in the patient-oriented research workforce.

Applications due October 12, 2016

  NCI Mentored Research Scientist Development Award to Promote Diversity (K01) (Deadline: 10/12/16)

NCI Mentored Research Scientist Development Award to Promote Diversity (K01)

The purpose of the NCI Mentored Research Scientist Development Award (K01) is to enhance the diversity of the NCI-funded cancer research workforce by supporting eligible individuals from groups that have been shown to be underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor, or sponsor.

The Diversity Training Branch (DTB) of the Center to Reduce Cancer Health Disparities (CRCHD), at the National Cancer Institute (NCI), invites career development award applications (K01) from individuals from backgrounds that have been shown to be underrepresented in health-related science.

Applications due October 12, 2016

  New Informatics Tools and Methods to Enhance U.S. Cancer Surveillance Research (UG3/UH3) (Deadline: 10/14/16)

New Informatics Tools and Methods to Enhance U.S. Cancer Surveillance Research (UG3/UH3)

The goal of this Funding Opportunity Announcement (FOA) is to advance surveillance science by supporting the development of new and innovative tools and methods for more efficient, detailed, timely, and accurate data collection by cancer registries. Specifically, the FOA seeks applications for projects to develop, adapt, apply, scale-up, and validate tools and methods to improve the collection and integration cancer registry data and to expand the data items collected. Applications must be built on partnership with U.S. population-based central cancer registries (a partnership must involve at least two different registries). Tools and methods proposed for development are expected to enhance the registry core infrastructure and, in so doing, expand the usefulness of registry-collected data to support high-quality cancer research.

The scientific scope of this FOA includes but is not limited to:

  • Development, validation, evaluation of scalable tools/methods to facilitate automatic/unsupervised extraction of specific data from various types of unstructured medical records as for example, pathology reports, diagnostic imaging, laboratory, discharge and clinical visits;
     
  • Supplementation of cancer registries with new or more detailed data items, from existing data sources or from linkages with novel data sources, e.g. electronic medical records (EMR)

UG3 Investigators applying to this FOA must apply for both the UG3 and UH3 phases together. The initial UG3 exploratory phase will be a feasibility study to demonstrate technical functionality and potential of the proposed tools/methods in a U.S. population-based central cancer registry by meeting specific performance milestones. UG3 projects that have met their milestones will be administratively considered by NCI and prioritized for transition to the UH3 validation phase. UH3 awards will support scalability, portability and implementation of the tools/methods in additional U.S. population-based central cancer registries (at least 1 more cancer registry).

Applications due October 14, 2016

  Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies (R33) (Deadline: 10/16/16)

Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies (R33)

Successful aging research frequently depends on collaborations that draw on expertise from a variety of disciplines. Established interdisciplinary research networks can provide the environment for increased sustainable research infrastructure and the opportunity to advance complex research activities through progressive stages of development. A classic example is translating interventions with demonstrated success in efficacy trials into real-world settings. This FOA is intended to provide the needed resources to existing interdisciplinary collaborative groups to meet the challenge of developing effective research infrastructure in important aging topics.

This FOA invites applications that propose to support advanced-stage development and utilization of novel research infrastructure to advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Exploratory/Developmental Grants Phase II mechanism to provide support for expanded activities. Applicants are expected to have an existing research infrastructure developed either through PA-12-064, or with other NIH or non-NIH support. Through this award, investigators will develop a mature and sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.

Applications due October 16, 2016

  Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R03) (Deadline: 10/16/16)

Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R03)

This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.

Applications due October 16, 2016

  Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R21) (Deadline: 10/16/16)

Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R21)

This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes.

Applications due October 16, 2016

  Mechanisms of Cancer and Treatment-related Symptoms and Toxicities (R21) (Deadline: 10/16/16)

Mechanisms of Cancer and Treatment-related Symptoms and Toxicities (R21)

This Funding Opportunity Announcement (FOA) invites innovative pilot projects or feasibility studies to stimulate research aimed to better understand the complex interaction of biological, cognitive, behavioral, and sociocultural factors that contribute to cancer and treatment related symptoms and toxicities throughout the cancer care trajectory. Data from the preliminary studies would be used to validate and extend the findings in larger cohort studies and/or test novel, mechanistically-driven interventions via the R01 funding mechanism. Of particular interest is to gain new insights about these factors, either alone or in combination, in minority, underserved, the elderly, and pediatric and young adult populations. Specifically, the FOA aims to identify, describe, and quantify these factors associated with acute and chronic cancer and treatment related symptoms and toxicities.

Applications due October 16, 2016

  Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection (R01) (Deadline: 10/16/16)

Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection (R01)

This Funding Opportunity Announcement (FOA) encourages research projects that focus on innovative research in the isolation and characterization of exosomes and their cargo for discovery of predictive biomarkers for risk assessment, detection, diagnosis and prognosis of early cancer. This FOA will promote rigor and reproducibility research in both the isolation of exosomes as well as the computational analysis of the cargo carried in these vesicles.

Applications due October 16, 2016

  Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection (R21) (Deadline: 10/16/16)

Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection (R21)

This Funding Opportunity Announcement (FOA) encourages research projects that focus on innovative research in the isolation and characterization of exosomes and their cargo for discovery of predictive biomarkers for risk assessment, detection, diagnosis and prognosis of early cancer. This FOA will promote rigor and reproducibility research in both the isolation of exosomes as well as the computational analysis of the cargo carried in these vesicles.

Applications due October 16, 2016

  Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33) (Deadline: 10/16/16)

Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33)

Successful aging research frequently depends on collaborations that draw on expertise from a variety of disciplines. In some cases, these collaborations arise naturally, but in other cases, organizational or fiscal obstacles hinder their effective development. Bridging data platforms, crossing inter-departmental silos, and other such challenges may pose substantial barriers to scientific progress despite the availability of personnel and resources. At the same time, innovative scientific findings often lead to novel opportunities that require the development of new collaborations. A classic example is translating interventions with demonstrated success in efficacy trials into real-world settings. This FOA is intended to provide the needed resources to interdisciplinary collaborative groups to meet the challenge of developing effective research infrastructure in important aging topics.

This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities, and up to 3 years of R33 support for expanded activities. Through this award, investigators will develop a sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.

Applications due October 16, 2016

  Small Research Grants for Analyses of Data for the Gabriella Miller Kids First Data Resource (R03) (Deadline: 10/16/16)

Small Research Grants for Analyses of Data for the Gabriella Miller Kids First Data Resource (R03)

The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotype data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. The overall goal of the Gabriella Miller Kids First Pediatric Data Resource is to help researchers understand the underlying mechanisms of these conditions, leading to more refined diagnostic capabilities and ultimately more targeted therapies, as well as to develop an integrated pediatric research data resource by obtaining and aggregating genome sequence and phenotype data for as many relevant structural birth defects and pediatric cancer cohorts as possible and to advance research in this area through the broad sharing of these data with the research community. This FOA is intended to promote meritorious small research projects focused on the development and analyses of childhood cancer and/or structural birth defects datasets that are part of the Kids First Data Resource or could be included in the Kids First Data Resource. Development of statistical methodology appropriate for analyzing genome-wide data relevant to childhood cancer and/or structural birth defects may also be proposed.

Applications due October 16, 2016

  Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21) (Deadline: 10/16/16)

Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve any aspect of the cancer continuum and any phase of the translational spectrum.

Applications due October 16, 2016

  Exploratory/Developmental Surgical Disparities Research (R21) (Deadline: 11/4/16)

Exploratory/Developmental Surgical Disparities Research (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to encourage developmental and exploratory research focused on understanding and addressing disparities in surgical care and outcomes, in minority and health disparity populations. The goal is to better understand and explore effectiveness of clinical intervention approaches for addressing surgical disparities, while employing multi-level strategies at the institutional and systems level.

Applications due November 4, 2016

  Role of the Microflora in the Etiology of Gastro-Intestinal Cancer (R01) (Deadline: 11/4/16)

Role of the Microflora in the Etiology of Gastro-Intestinal Cancer (R01)

This Funding Opportunity Announcement (FOA) encourages innovative multidisciplinary research projects that will advance our mechanistic understanding of microflora influences on Gastro-Intestinal (GI) carcinogenesis. Recent advances in our knowledge of GI microflora composition and function have generated a flood of new information, technologies, and capabilities that may for the first time allow mechanistic investigations of very complex, networked host/microbiome interactions on a systems wide scale. This FOA encourages investigators to ingrate this new information into hypothesis-driven studies that can define and validate molecular mechanisms that determine microbe-induced carcinogenic outcomes. Applicants may integrate information from existing large data sets, including metagenomic data sets, or may also propose to generate appropriate new data sets, including but not limited to analysis of host and microbial genomes, proteomes, metabalomes, post-translational modifications, secreted signals, and protein-protein interaction data. An additional goal of this program is to encourage collaborative efforts between scientists currently engaged in GI cancer research with those in scientific disciplines that may not otherwise apply their expertise to study cancer etiology and prevention. Investigators particularly from the disciplines of microbiology, microbial ecology, molecular biology, immunology, nutrition sciences, bioinformatics, and computational sciences are encouraged to apply. A value added from stimulating integrated, multidisciplinary experimental approaches may include the discovery of emergent properties of the GI ecosystem that could not be elucidated using either descriptive bioinformatics or molecular studies alone.

Applications due November 4, 2016

  Surgical Disparities Research (R01) (Deadline: 11/4/16)

Surgical Disparities Research (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on understanding and addressing disparities in surgical care and outcomes, in minority and health disparity populations. While the goal is to better understand and explore effectiveness of clinical intervention approaches for addressing surgical disparities, this initiative will also seek to identify multi-level strategies at the institutional and systems level.

Applications due November 4, 2016

  Core Clinical Centers for the Blood and Marrow Transplant Clinical Trials Network (UG1) (Deadline: 11/10/16)

Core Clinical Centers for the Blood and Marrow Transplant Clinical Trials Network (UG1)

This Funding Opportunity Announcement (FOA) invites applications to participate as a Core Clinical Center/Consortia in the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). This collaborative multi-center clinical program promotes the efficient comparison of novel treatment approaches and management strategies for potential benefit of children and adults undergoing hematopoietic stem cell transplantation (HCT), either alone or in combination with novel cell-based therapies. Collaboration among the Core Clinical Centers, the Data Coordinating Center, the NHLBI, the NCI, and other stakeholders will permit multi-center evaluation of new HCT approaches with attention to treatment of malignant and non-malignant blood diseases. During this funding cycle, the BMT CTN will have the flexibility to conduct early phase multi-center HCT trials incorporating novel cell therapies, and to expand the use of promising products from highly selected to more heterogeneous patient populations.

The overall goals of the BMT CTN are to improve HCT outcomes, evaluate promising novel cell therapies, and rapidly disseminate study results to improve the scientific basis for the treatment of patients in need of HCT therapy.

Applications due November 10, 2016

  Limited Competition: Data Coordinating Center for the Blood and Marrow Transplant Clinical Trials Network (U24) (Deadline: 11/10/16)

Limited Competition: Data Coordinating Center for the Blood and Marrow Transplant Clinical Trials Network (U24)

This Funding Opportunity Announcement (FOA) announces a limited competition opportunity to support the Data Coordinating Center (DCC) for the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Only the current awardees of the BMT CTN DCC are eligible to apply.

This collaborative multi-center clinical program promotes the efficient comparison of novel treatment approaches and management strategies for potential benefit of children and adults undergoing hematopoietic stem cell transplantation (HCT), either alone or in combination with novel cell-based therapies. Collaboration among the Core Clinical Centers, the DCC, the NHLBI, the NCI, and other stakeholders will permit multi-center evaluation of new HCT approaches with attention to treatment of malignant and non-malignant blood diseases. During this funding cycle, the BMT CTN will have the flexibility to conduct early phase multi-center HCT trials incorporating novel cell therapies, and to expand the use of promising products from highly selected to more heterogeneous patient populations. The overall goals of the BMT CTN are to improve HCT outcomes, evaluate promising novel cell therapies, and rapidly disseminate study results to improve the scientific basis for the treatment of patients in need of HCT therapy.

The awardee to this FOA will provide the relevant medical and scientific expertise, as well as overall coordination, data management, regulatory, statistical/analytical, and operational support for the program.

Applications due November 10, 2016

  NIH Big Data to Knowledge (BD2K) Enhancing Diversity in Biomedical Data Science (R25) (Deadline: 11/14/16)

NIH Big Data to Knowledge (BD2K) Enhancing Diversity in Biomedical Data Science (R25)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIH Big Data to Knowledge (BD2K) Enhancing Diversity in Biomedical Data Science (R25) program is to support educational activities that enhance the diversity of the biomedical, behavioral, and clinical research workforce. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on research experiences and curriculum or methods development.

Applications due November 14, 2016

  Social Epigenomics Research Focused on Minority Health and Health Disparities (R01) (Deadline: 11/15/16)

Social Epigenomics Research Focused on Minority Health and Health Disparities (R01)

The overarching objectives of this initiative are to (1) advance the science of epigenomics focused on minority health and health disparities, (2) expand approaches for understanding epigenetic mechanisms by which social factors lead to biological changes that affect health disparities, and (3) promote epigenetics research to better diagnose disease risk or resiliency among disadvantaged populations. Successful projects will support human-based epigenomic research, with a particular focus on the identification and study of human epigenetic marks that are of social origin or are substantially influenced at a population level by social processes.

Projects should include a focus on one or more NIH-designated health disparity populations in the United States, which include Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asian Americans, Native Hawaiians and other Pacific Islanders, socioeconomically disadvantaged populations, and underserved rural populations.

This initiative is also intended to promote collaborations that will combine the knowledge and scientific expertise of social scientists, public health researchers and molecular biologists to develop innovative strategies to understand the interaction and linkage of epigenetics mechanisms to multiple factors that may create or contribute to the persistence of health disparities. Interdisciplinary efforts are encouraged, including bioinformatics, biostatistics, molecular biology, epidemiology, social sciences, public health and clinical medicine, to tackle the complex issues associated with health disparities.

Applications due November 15, 2016

  Social Epigenomics Research Focused on Minority Health and Health Disparities (R21) (Deadline: 11/15/16)

Social Epigenomics Research Focused on Minority Health and Health Disparities (R21)

The overarching objectives of this initiative are to (1) advance the science of epigenomics focused on minority health and health disparities, (2) expand approaches for understanding epigenetic mechanisms by which social factors lead to biological changes that affect health disparities, and (3) promote epigenetics research to better diagnose disease risk or resiliency among disadvantaged populations. Successful projects will support human-based epigenomic research, with a particular focus on the identification and study of human epigenetic marks that are of social origin or are substantially influenced at a population level by social processes.

Projects should include a focus on one or more NIH-designated health disparity populations in the United States, which include Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asian Americans, Native Hawaiians and other Pacific Islanders, socioeconomically disadvantaged populations, and underserved rural populations.

This initiative is also intended to promote collaborations that will combine the knowledge and scientific expertise of social scientists, public health researchers and molecular biologists to develop innovative strategies to understand the interaction and linkage of epigenetics mechanisms to multiple factors that may create or contribute to the persistence of health disparities. Interdisciplinary efforts are encouraged, including bioinformatics, biostatistics, molecular biology, epidemiology, social sciences and clinical medicine, to tackle the complex issues associated with health disparities.

Applications due November 15, 2016

  Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24) (Deadline: 11/17/16)

Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24)

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve correlation of results for co-clinical trials.

The scientific goals of this FOA are to: (a) perform the appropriate optimization of the pre-clinical quantitative imaging methods, (b) implement the optimized methods in the co-clinical trial, and finally (c) populate a web-accessible research resource with all the data, methods, workflow documentation, and results collected from the co-clinical investigations.

Co-clinical trials are defined in this FOA as investigations in patients and in parallel (or sequentially) in mouse or human-in-mouse models of cancer that mirror the genetics and biology of the patients’ malignancies or pre-cancerous lesions.

The co-clinical trial should include either (a) a therapeutic goal, such as the prediction, staging, and/or measurement of tumor response to therapies, or (b) a screening and early detection or a cancer risk stratification goal for lethal cancer versus non-lethal disease.

Applicants are encouraged to organize multi-disciplinary teams with experience in mouse models research, human investigations, imaging platforms, QI methods, decision support software and informatics to populate the research resource.

Applications due November 17, 2016

  Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24) (Deadline: 11/17/16)

Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24)

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve the quality of imaging results for co-clinical trials.

The scientific goals of this FOA are to: (a) perform the appropriate optimization of the pre-clinical quantitative imaging methods, (b) implement the optimized methods in the co-clinical trial, and finally (c) populate a web-accessible research resource with all the data, methods, workflow documentation, and results collected from the co-clinical investigations.

Co-clinical trials are defined in this FOA as investigations in patients and in parallel (or sequentially) in mouse or human-in-mouse models of cancer that mirror the genetics and biology of the patients' malignancies or pre-cancerous lesions. The co-clinical trial should include either (a) a therapeutic goal, such as the prediction, staging, and/or measurement of tumor response to therapies, or (b) a screening and early detection or a cancer risk stratification goal for lethal cancer versus non-lethal disease.

Applicants are encouraged to organize multi-disciplinary teams with experience in mouse models research, human investigations, imaging platforms, QI methods, decision support software and informatics to populate the research resource.

Applications due November 17, 2016

  Advanced Development of Informatics Technologies for Cancer Research and Management (U24) (Deadline: 11/21/16)

Advanced Development of Informatics Technologies for Cancer Research and Management (U24)

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum, including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities.

As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Initiative, this FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field.

In addition, mechanisms to solicit feedback from users and collaborators throughout the development process should be included. Potential applicants who are interested in early-stage development or informatics resource sustainment should consult companion FOAs listed above.

Applications due November 21, 2016

  NCI Outstanding Investigator Award (R35) (Deadline: 11/22/16)

NCI Outstanding Investigator Award (R35)

This Funding Opportunity Announcement (FOA) invites grant applications for the Outstanding Investigator Award (R35) in any area of cancer research.

The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/PIs) for the NCI OIA.

It is expected that the OIA would provide extended funding stability and encourage investigators to embark on projects of unusual potential in cancer research. The research projects should break new ground or extend previous discoveries toward new directions or applications that may lead to a breakthrough that will advance biomedical, behavioral, or clinical cancer research.

Applications due November 22, 2016

  BD2K Research Education Curriculum Development: Data Science Overview for Biomedical Scientists (R25) (Deadline: 12/7/16)

BD2K Research Education Curriculum Development: Data Science Overview for Biomedical Scientists (R25)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this BD2K R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Curriculum or Methods Development in Big Data Science to augment current institutional curricula for the training of pre-doctoral level biomedical scientists and provide concentrated instruction in the tools, approaches and quantitative analysis concepts in data science. To facilitate the integration of data science into biomedical curricula nationally, this FOA seeks to support a cohort of institutions that will work collaboratively and collectively to produce curricular materials that are findable, accessible, interoperable, and reusable (FAIR).

Applications due December 7, 2016

  Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01) (Deadline: 2/15/17)

Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01)

This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data.

This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.

Applications due February 15, 2017

  Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01) (Deadline: 4/11/17)

Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to encourage projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum.

The FOA is expected to encourage collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and decision sciences with downstream implications for cancer prevention and control.

Applications due April 11, 2017

National Institutes of Health (NIH)

Open AllClose All
  Time-Sensitive Obesity Policy and Program Evaluation (R01)

Time-Sensitive Obesity Policy and Program Evaluation (R01)

This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding.

All applications to this FOA must demonstrate that the evaluation of an obesity related policy and /or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications in response to this time-sensitive FOA are not eligible for resubmission. It is intended that eligible applications selected for funding will be awarded within four months of the application due date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.

Applications due on a continuous basis (once per month)

Department of Defense (DOD)

Open AllClose All
  Peer Reviewed Cancer Research Program (PRCRP) - Horizon Award (Deadline: 9/28/16)

Peer Reviewed Cancer Research Program (PRCRP) – Horizon Award

The goal of the PRCRP is to improve quality of life by decreasing the impact of cancer on active duty Service members, their families, and the American public. The PRCRP is charged by Congress with the mission to investigate cancer risks and knowledge gaps that may be relevant to active duty Service members, their families, and other military beneficiaries.

Applications due September 28, 2016

  Prostate Cancer Research Program (PCRP) - Clinical Consortium Research Site Award (Deadline: 10/6/16)

Prostate Cancer Research Program (PCRP) – Clinical Consortium Research Site Award

The mission of the FY16 PCRP is to find and fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of men experiencing the impact of the disease. Specifically, the PCRP seeks to promote highly innovative, groundbreaking research; high-impact research with near-term clinical relevance; multidisciplinary, synergistic research; translational studies to support the fluid transfer of knowledge between bedside and bench; research on patient survivorship and quality of life; the next generation of prostate cancer investigators through mentored research; and research on disparities in the incidence and mortality of prostate cancer.

Applications due October 6, 2016

  Breast Cancer Research Program (BCRP) – Breakthrough Award – Levels 3 and 4 (Deadline: 12/8/16)

Breast Cancer Research Program (BCRP) – Breakthrough Award – Levels 3 and 4

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are:

Impact
Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must be significant and move beyond an incremental advancement. Applications must articulate the pathway to making a clinical impact for individuals with, or at risk for, breast cancer, even if clinical impact is not an immediate outcome.

Research Scope
Research proposed under this award mechanism may be small - to large - scale projects, at different stages of idea and research development.

The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level:

Funding Level 3
Advanced translational studies that have potential for near-term clinical investigation. Small-scale clinical trials may apply.

Funding Level 4
Large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer. Near-term clinical impact is expected. PIs are expected to have experience in successfully leading large-scale projects.

Considering the current breast cancer landscape and the BCRP's vision to end breast cancer, each FY16 Innovator Award application must address one or more of the following overarching challenges. Alternatively, with adequate justification, applications may identify and address another overarching challenge related to the breast cancer landscape. Justification must be provided in the application.

  • Prevent breast cancer (primary prevention);
  • Identify what makes the breast susceptible to cancer development
  • Determine why some, but not all, women get breast cancer;
  • Distinguish aggressive breast cancer from indolent cancers;
  • Conquer the problems of over-diagnosis and overtreatment;
  • Identify what drives breast cancer growth; determine how to stop it;
  • Identify why some breast cancers become life - threatening metastasis;
  • Determine why/how breast cancer cells lay dormant for years and then re-emerge (recurrence); determine how to prevent recurrence;
  • Revolutionize treatment regimens by replacing interventions that have life-threatening toxicities with ones that are safe and effective; and
  • Eliminate the mortality associated with metastatic breast cancer.

Pre-Applications due September 14, 2016

Applications due December 8, 2016

Foundations & Organizations

Open AllClose All
  Clinical Investigator Career Development Award (2017-2020) | Lymphoma Research Foundation (Deadline: 8/31/16)

Clinical Investigator Career Development Award (2017-2020) | Lymphoma Research Foundation

The Lymphoma Research Foundation (LRF) maintains a strong commitment to supporting young investigators and ensuring they can build a successful career in the field of lymphoma research. The LRF Clinical Investigator Career Development Award (CDA) Program is designed to support physician investigators at the level of advanced fellow or junior faculty member who will contribute to the development of new lymphoma therapies and diagnostic tools. Eligible investigators must have no greater than five years of experience beyond completion of their fellowship or post-doctoral training (the five year limit may be non-sequential in cases of pregnancy or illness).

The goal of the program is to prepare physician investigators to design and administer clinical research studies in lymphoma and assume primary responsibilities for clinical research, protocol writing, Institutional Review Board (IRB) submission and publication. As such, a Career Development Plan is required as part of the Grant Application. The proposed research plan should also develop the necessary knowledge and clinical research skills relevant to the investigator’s career goals. The Grant is designed to provide physician investigators with support to spend 35-50 percent of their time implementing clinical research studies in lymphoma.

The LRF Clinical Investigator Career Development Award provides a total of $225,000 to grantees over three years. The Grant provides salary support in the amount of $70,000 per year. Incidental funds of $5,000 per year which may be budgeted for research supplies or professional development expenses such as tuition, registration fees, and travel for courses and meetings that are integral to the Career Development Plan. This Grant does not provide institutional overhead.

Applications due August 31, 2016

  Clinical Investigator Career Development Grant | Lymphoma Research Foundation (Deadline: 8/31/16)

Clinical Investigator Career Development Grant | Lymphoma Research Foundation

The Lymphoma Research Foundation (LRF) maintains a strong commitment to supporting young investigators and ensuring they can build a successful career in the field of lymphoma research. The LRF Clinical Investigator Career Development Grant Program is designed to support physician investigators at the level of advanced fellow or junior faculty member who will contribute to the development of new lymphoma therapies and diagnostic tools.

The goal of the program is to prepare physician investigators to design and administer clinical research studies in lymphoma and assume primary responsibilities for clinical research, protocol writing, Institutional Review Board (IRB) submission and publication. As such, a Career Development Plan is required as part of the Grant Application. The proposed research plan should also develop the necessary knowledge and clinical research skills relevant to the investigator's career goals. The Grant is designed to provide physician investigators with support to spend 35-50 percent of their time implementing clinical research studies in lymphoma.

Applications due August 31, 2016

  Lymphoma Clinical Research Mentoring Program (2017-2019) | Lymphoma Research Foundation (Deadline: 8/31/16)

Lymphoma Clinical Research Mentoring Program (2017-2019) | Lymphoma Research Foundation

A Training Program for Hematology/Oncology Fellows and Junior Faculty with a focus on Clinical Research in Lymphoma.

The Lymphoma Research Foundation (LRF) Lymphoma Clinical Research Mentoring Program (LCRMP) is an education and mentoring program for fellows and junior faculty with a focus in clinical research in the field of non-Hodgkin and Hodgkin lymphoma. The program is two years in length and offers a broad education on clinical research and career development as well as managing career and quality of life issues. The goals of the LCRMP include:

  • Provide mentoring and education to hematology/oncology fellows and junior faculty. The program will emphasize training in clinical research methods and design, statistical analysis, pathology, incorporating and interpreting correlative studies into clinical trials, and grant submission and funding. The program also aims to foster mentorship and research collaboration among experts and trainees in the field.
     
  • Assist in the development of a specific clinical trial in patients with lymphoma and to set the foundation for grant development to support the trial. Study design and implementation will be discussed in a small group setting consisting of experts in the field, statisticians, and other trainees in the program, where information, ideas, guidance, support and connections are shared, and where mentoring relationships can be developed.
     
  • Provide continuing training, career development advice, and mentorship among trainees and experts in the field and to foster future participation and collaboration within the LRF through follow-up programming and activities.

Applications due August 31, 2016

  Postdoctoral Fellowships (2017-2019) | Lymphoma Research Foundation (Deadline: 8/31/16)

Postdoctoral Fellowships (2017-2019) | Lymphoma Research Foundation

The Lymphoma Research Foundation (LRF) maintains a strong commitment to supporting young investigators and ensuring they can build a successful career in the field of lymphoma research. The LRF Postdoctoral Fellowship Grant is designed to support investigators at the level of advanced fellow or postdoctoral researcher in laboratory or clinic based research with results and conclusions that must be clearly relevant to the treatment, diagnosis or prevention of Hodgkin and/or non-Hodgkin lymphoma. Areas of research may include, but are not limited to, etiology, immunology, genetics, therapies and transplantation. Historically, successful applications in this program have focused on basic, translational, and epidemiological research. The Fellow must spend 80 percent of their time in research during the award period.

The LRF Postdoctoral Fellowship provides a total of $105,000 to grantees over two years. Salary support is provided in the amount of $45,000 for the first year and $50,000 for the second year. Incidental funds of $5,000 per year may be budgeted for research supplies or professional development expenses such as tuition, registration fees, and travel for courses and meetings. This Grant does not provide for institutional overhead.

Applications due August 31, 2016

  Postdoctoral Fellowship Grants | Lymphoma Research Foundation (Deadline: 8/31/16)

Postdoctoral Fellowship Grants | Lymphoma Research Foundation

The LRF maintains a strong commitment to supporting young investigators and ensuring they can build a successful career in the field of lymphoma research. The LRF Postdoctoral Fellowship Grant is designed to support… more » investigators at the level of advanced fellow, postdoctoral researcher, or junior faculty member in laboratory or clinic based research with results and conclusions that must be clearly relevant to the treatment, diagnosis or prevention of Hodgkin and/or non-Hodgkin lymphoma. Areas of research may include, but are not limited to, etiology, immunology, genetics, therapies and transplantation. During the award period, the Fellow must spend a minimum of 80 percent of his/her time in research without major patient care, teaching, or administrative responsibilities except as such responsibilities relate directly to a pre-clinical or clinical lymphoma research project.

Applications due August 31, 2016

  American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation (Deadline: 9/22/16)

American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation

The CDA provides funding to clinical investigators who have received their initial faculty appointment to establish an independent clinical cancer research program. The foundation welcomes application submissions in all oncology subspecialties.

The CDA is intended to support proposals with a clinical research focus. ASCO's definition of clinical research is "hypothesis-driven research that employs measurements in whole patients or normal human subjects, in conjunction with laboratory measurements as appropriate, on the subjects of clinical biology, natural history, prevention, screening, diagnosis, therapy, or epidemiology of neoplastic disease" (Journal of Clinical Oncology, Vol. 14, No. 2, 1996 pp. 666-670).

Proposals must have a patient-oriented focus including a clinical research study involving human subjects. Proposals with a predominant focus on in vitro or animal studies (even if clinically relevant) are not allowed. Project proposals should have measurable outcomes during the grant period.

Applications due September 22, 2016

  Young Investigator Award | Conquer Cancer Foundation (Deadline: 9/22/16)

Young Investigator Award | Conquer Cancer Foundation

The Young Investigator Award (YIA) provides funding to promising investigators to encourage and promote quality research in clinical oncology. The purpose of this grant is to fund physicians during the transition from a fellowship program to a faculty appointment.

The Young Investigator Award is a one-year grant totaling $50,000 to pay for personnel and/or research expenses, and travel to attend the CCF Grants and Awards Ceremony at the ASCO Annual Meeting. The number of YIA grants in each funding cycle is not predetermined by the Conquer Cancer Foundation. Awards are given based on individual merit and availability of funds.

Applications due September 22, 2016

  Albert Szent-Gyorgyi Prize for Progress in Cancer Research (Deadline: 9/30/16)

Albert Szent-Gyorgyi Prize for Progress in Cancer Research

The Albert Szent-Györgyi Prize for Progress in Cancer Research is named in honor of Doctor Albert Szent-Györgyi, Nobel Prize Winner and co-founder of NFCR (1893-1986). The prize is a symbol of NFCR's enduring commitment to uphold Dr. Szent-Györgyi's vision of curing cancer through innovation and collaboration. We established this annual prize to honor scientists who have made extraordinary progress in cancer research, and to focus attention on the essential role of basic research in understanding cancer. In addition to the coveted award, prize recipients are also given a $25,000 grant to further their research, and attend a gala in their honor. In addition to rewarding scientific leaders, this prize also serves to stimulate continued investment in pioneering research that produces scientific breakthroughs and leads to deeper understanding of the genetic and molecular makeup of cancer. By calling attention to achievements in this area, we hope to heighten awareness of the kind of research that must be accomplished before we can hope to produce cancer cures.

Nominations due September 30, 2016

  Scholar in Clinical Research Awards | Leukemia & Lymphoma Society (LLS) (Deadline: 10/3/16)

Scholar in Clinical Research Awards | Leukemia & Lymphoma Society (LLS)

The award is for investigators conducting original, independent applied research, often involving early-stage clinical trials that will advance the prevention, diagnosis or treatment of hematologic malignancies.

The award is intended to further develop the independent research careers of highly qualified investigators, not to support well-established or senior investigators. The proposed studies should translate new concepts in the biomedical, epidemiological, or preventive sciences into clinical practice. Preference will be given to applicants whose research involves an early phase clinical trial of new or innovative therapies.

Any proposed clinical research should be independently developed and implemented by the applicant. Ongoing collaborations and sponsorships of clinical research by an industry source are acceptable.

Applications due October 3, 2016

  Research Grants Program | Skin Cancer Foundation (Deadline: 10/14/16)

Research Grants Program | Skin Cancer Foundation

The Foundation is now accepting applications for support of pilot research projects related to skin cancer. The foundation funds basic research and clinical studies which address improved methods of prevention detection, and treatment of skin cancer. Researchers are invited to submit applications for one-year projects to be conducted within the dermatology departments of medical institutions within the U.S. The Foundation's mission is to decrease the incidence of the disease by means of public and professional education, and research.

Applications due October 14, 2016

  American Board of Obstetricians and Gynecologists (ABOG) Young Investigator Career Development Award (Deadline: 10/28/16)

American Board of Obstetricians and Gynecologists (ABOG) Young Investigator Career Development Award

The purpose of the award is to support, attract and train promising clinical scientists who are embarking on careers dedicated to gynecologic cancer research. By providing funding to trainees under the supervision of a mentor, FWC seeks to ensure the next generation of scientists proficient in gynecologic cancer translational and/or clinical research.

This funding mechanism offers two different research focus areas: 1) Basic/Translational; and 2) Clinical. The award will support a one-year period of mentored research. Basic/translational awards aim to integrate mechanistic studies with biologically-based research. The experience is intended to be of both intrinsic research importance as well as a vehicle for learning the methodology, theories and conceptualizations necessary for a well-trained independent investigator able to translate laboratory findings into the clinical setting. Clinical awards will support hypothesis-driven, patient-oriented research where an investigator interacts with human subjects or patients to test efficacy of interventions, treatments and/or quality of life issues related to their disease.

Applications due October 28, 2016

  Genentech Ovarian Cancer Young Investigator Career Development Award | Foundation for Women's Cancer/Society of Gynecologic Oncology (Deadline: 10/28/16)

Genentech Ovarian Cancer Young Investigator Career Development Award | Foundation for Women's Cancer/Society of Gynecologic Oncology

FWC has merged with the Society of Gynecologic Oncology's (SGO's) Foundation for Gynecologic Oncology and is now the official foundation of the SGO. FWC offers this grant to support cancer research. Research priorities of particular interest to the Foundation fall into the following category:

Ovarian Carcinoma

  • Origins of ovarian cancer
  • Tumor microenvironment and metabolic circuits in ovarian carcinoma
  • Translational interrogation of patient samples from innovative clinical trials
  • Drug sensitivity and resistance
  • Defining the complete molecular spectrum of ovarian cancer; prevention, early detection, surveillance

The purpose of these awards is to train junior investigators to become independent investigators to ensure the next generation of scientists proficient in gynecologic cancer translational research. The awards will support a two-year period of mentored research that integrates mechanistic studies with biologically-based research. The experience is intended to be of both intrinsic research importance as well as a vehicle for learning the methodology, theories and conceptualizations necessary for a well-trained independent investigator able to translate laboratory findings into the clinical setting.

Applications due October 28, 2016

  Genentech Gynecologic Cancer Young Investigator Career Development Award | Foundation for Women's Cancer/Society of Gynecologic Oncology (Deadline: 10/28/16)

Genentech Gynecologic Cancer Young Investigator Career Development Award | Foundation for Women's Cancer/Society of Gynecologic Oncology

The purpose of these awards is to train junior investigators to become independent investigators to ensure the next generation of scientists proficient in gynecologic cancer translational research. The awards will support a two-year period of mentored research that integrates mechanistic studies with biologically-based research. The experience is intended to be of both intrinsic research importance as well as a vehicle for learning the methodology, theories and conceptualizations necessary for a well-trained independent investigator able to translate laboratory findings into the clinical setting.

Applications due October 28, 2016

  Postdoctoral Fellowship (PDF) Grants - Clinical Research | Komen for the Cure, Susan G. (Deadline: 11/11/16)

Postdoctoral Fellowship (PDF) Grants - Clinical Research | Komen for the Cure, Susan G.

PDF Grants are intended to attract and preserve today's young scientists and clinicians who will fuel the future and become the next generation of leaders in the field of breast cancer research. These leaders will play key roles in reducing breast cancer incidence and mortality within the next decade, with the ultimate goal of ending breast cancer forever.

LOI due July 14, 2016

Applications due November 11, 2016

  Damon Runyon Physician-Scientist Training Award (Deadline: 12/1/16)

Damon Runyon Physician-Scientist Training Award

This is a pilot program, which will award up to 3 awards per year initially. The future size of the program will be judged based upon its progress, success, and the amount of available funding. The award will be for a period of four years. Funding will be allocated to the awardee's institution each year for the support of the scientist. Funds are to be used for stipend and/or research expenses. No part of this grant can be used for indirect costs or institutional overhead.

Debt Repayment Program
The Damon Runyon Cancer Research Foundation will retire up to $100,000 of any qualifying medical school debt still owed by the awardee. Payment will be 50% of the outstanding debt during the award period and 50% upon completion of the program, if the awardee demonstrates a commitment and intent to continue a career as a physician-scientist. Note: qualified candidates must first apply to the NIH Loan Repayment Program in order to be eligible for loan repayment from Damon Runyon. Awardees may receive funding from other sources to support their research. However, no other physician-scientist career development award from a private source or federal government (e.g., K08 or K23) may be held concurrently with this award.

All awards are made to the sponsoring institution for support of the designated awardee. An award does not constitute an employer-employee relationship between the Foundation and the recipient. Physician-scientists must devote their principal time and effort (at least 80 percent) to Damon Runyon-supported research activities. The Damon Runyon Foundation will allow up to 12 weeks of paid parental leave for birth/adoptive parents consistent with their institution's policy. The Foundation must be notified in advance of the leave. If the Awardee transitions to an assistant professorship appointment (or equivalent) during the award term, he/she must terminate the award.

Should the Awardee and/or Mentor wish to discontinue the project, leave the designated institution or modify any aspect of the award, he or she must seek approval from the Damon Runyon Cancer Research Foundation in advance. Failure to comply with this requirement may jeopardize any future awards to the institution and/or Mentor by the Foundation.

Applications due December 1, 2016

  Graduate Training in Disparities Research (GTDR) | Komen for the Cure, Susan G. (Deadline: TBA)

Graduate Training in Disparities Research (GTDR) | Komen for the Cure, Susan G.

Graduate Training in Disparities Research (GTDR) Grants are intended to establish and/or to sustain a training program for graduate students who are seeking careers dedicated to understanding and eliminating disparities in breast cancer outcomes across population groups.

By providing funding to outstanding training programs, Komen seeks to ensure that a diverse pool of highly trained scientists will emerge as the next generation of leaders in the field of breast cancer research focused on disparities in breast cancer outcomes.

The research training program should be designed to meet the following goals:

  • Attract graduate students, specifically those from populations affected by disparities in breast cancer outcomes, into research careers.
     
  • Empower these students with the skills and knowledge necessary to effectively explore the causes of differential breast cancer outcomes and develop interventions to reduce and eliminate such disparities.

Deadline TBA

  Distinguished Scholars | Lustgarten Foundation

Distinguished Scholars | Lustgarten Foundation

The Distinguished Scholars program supports world-class scientists, who are at the top in their field, and are at the forefront of today's most exciting breakthroughs in pancreatic cancer research. Selected by The Lustgarten Foundation's Scientific Advisory Board (SAB), each grantee will receive $5 million in funding over the next five years, enabling these scientists to purse high-risk high-reward science, dedicate more of their time and focus to pancreatic cancer research, and accelerate a path to a cure.

The Distinguished Scholar Award is given on a discretionary basis and is not part of the annual grant program.

  Komen Southeast Wisconsin's Small Grant Program

Komen Southeast Wisconsin's Small Grant Program

Any non-profit organization in the Komen Southeast Wisconsin service area can apply for up to $5,000 for a small pilot or capacity-building breast health program grant. These grants are for organizations interested in beginning a new program or testing new ideas that will increase the innovative capacity and effectiveness of breast health programs that serve low income and uninsured women.

Small Grants are available in two categories:

  1. Education/Outreach Grants will support the development of breast cancer programs or projects.
     
  2. Capacity Building/Technical Assistance Grants will provide funding to increase the efficiency and effectiveness of an organization's ability to provide services by redesigning processes, implementing new practices, or developing collaborations or partnerships.

Applications due on a continuous basis throughout funding cycle

Pancreatic Cancer Action Network

Institutional

Open AllClose All
  Community Engagement Core (Deadline: 9/30/16)

Community Engagement Core

The CE Core is soliciting proposals for new CEnR projects for this funding program. The CE Core seeks to promote CEnR throughout all of MCW and support innovative CEnR including fostering community-academic partnerships. In addition to funding provided by the CE Core, funded projects will be matched by the Cancer Center at the Medical College of Wisconsin. The Cancer Center is dedicated to reducing the cancer burden through innovative research into its causes, prevention, early detection and treatment. For this grant cycle, all projects must select a research topic related to cancer.

Pre-proposals due August 19, 2016

Applications due September 30, 2016

Other

Open AllClose All
  A-T Children’s Project (Deadline: 9/1/16)

A-T Children's Project

Ataxia-telangiectasia, or A-T, is a rare genetic disease that attacks children, causing progressive loss of muscle control, immune system problems, and a high rate of cancer. A-T affects a large variety of systems in the body, causing symptoms that affect health and daily living.

The A-T Children's Project strives to assist respected scientists around the world in developing a clearer understanding of A-T. The A-T Children's Project is determined to find a timely cure, or life-improving treatments, for this serious disease. Postdoctoral fellowships are available.

The A-T Children's Project provides competitive grant awards for basic and translational research grants related to A-T.

The A-T Children's Project is currently focusing its funding efforts on proposals that apply innovative and novel strategies for suggesting, developing and evaluating specific disease-modifying and symptomatic interventions with an emphasis on: 1. translational (bench to bedside) research and 2. clinical studies. As such, these types of applications will be given priority funding.

Applications due September 1, 2016

  Gilead Sciences Research Scholars Program in Hematology/Oncology (Deadline: 9/2/16)

Gilead Sciences Research Scholars Program in Hematology/Oncology

The mission of the Gilead Sciences Research Scholars Program in Hematology/Oncology (the "program") is to support innovative scientific research that will advance knowledge in the field of hematology/oncology, with a focus on hematologic malignancies, and provide support for research career development. Gilead Sciences, Inc. hopes that the research supported by these awards will enhance understanding in hematology/oncology.

The program is designed to support innovative translational research projects in hematology/oncology, with a focus on hematologic malignancies, that can be either based around a clinical trial or laboratory investigation.

Awards granted under the program may not be duplicative of funding from institutional or hospital, other governmental, non-governmental, or industry sources. Applicants seeking an award for research projects that are currently receiving or may receive partial funding from other sources are required to submit appropriate evidence, including budget information related to the other sources, to demonstrate that there is no direct overlap in funding.

Applications due September 2, 2016

  Milstein Research Scholar Awards for Melanoma/Non-Melanoma Skin Cancer | American Skin Association (Deadline: 10/1/16)

Milstein Research Scholar Awards for Melanoma/Non-Melanoma Skin Cancer | American Skin Association

This award supports basic science and clinical research for melanoma/non-melanoma skin cancer by gifted investigators in the early phases of their careers. This program offers funds to foster the career development of a young investigator working in the field of dermatology or cutaneous biology. The aim of the program is to provide bridge support for young investigators.

The individual must have a strong career goal within the field of dermatology and be dedicated to the furtherance of knowledge concerning melanoma/non-melanoma skin cancer. The research must be focused on new discoveries in the basic or translational medical sciences that impact the understanding or treatment of melanoma/non-melanoma skin cancer.

Applications due October 1, 2016

  Career Development Program | Leukemia & Lymphoma Society (Deadline: 10/3/16)

Career Development Program | Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society's (LLS) Career Development Program (CDP) provides stipends so that you can devote yourself to researching questions of direct relevance to hematological malignancies and/or relevant pre-malignant conditions.

LLS offers career development awards to postdoctoral fellows as well as early career, independent investigators. Please verify in our guidelines and instructions which award is appropriate for your level of experience and apply to that category of award.

Applications due October 3, 2016

  Independent Grants for Learning & Change (IGL&C) - Latest Research Advances in CDK 4/6 Inhibition for Cancer Treatment Beyond Breast Cancer | Pfizer, Inc. (Deadline: 10/3/16)

Independent Grants for Learning & Change (IGL&C) – Latest Research Advances in CDK 4/6 Inhibition for Cancer Treatment Beyond Breast Cancer | Pfizer, Inc.

The mission of Pfizer Independent Grants for Learning & Change (IGL&C) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. "Independent" means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

Through this CGA Pfizer encourages organizations to submit grant requests that, if funded, will support education in a specific disease state, therapeutic area, or broader area of educational need.

For patients with metastatic breast cancer, CDK 4/6 inhibitors are available or currently being explored as potential treatment options. However, in addition to breast cancer, several CDK 4/6 inhibitors are being studied in multiple other solid tumor types including lung/head & neck cancers, GI tumors (colorectal, pancreatic), and gynecologic tumors, as well as for hematologic malignancies.

It is Pfizer's intent to support continuing professional development programs (including CME/CE) for pre-clinical and clinical researchers, medical oncologists and other healthcare professionals interested in understanding the research advances in this area.

Proposed programs should increase the awareness and understanding of the oncology community of the latest CDK 4/6 inhibitor research and explore the potential future role of CDK 4/6 inhibitors in multiple tumor types, beyond breast cancer. This may include pre-clinical data, biomarker targets, sensitivity and resistance mechanisms, and ongoing clinical trials. While programming targeted at addressing knowledge gaps may involve live sessions (e.g. conferences, satellite symposia, regional workshops), efforts should be made to encourage interaction, provide opportunities for discussion, and to extend and reinforce learning opportunities beyond the live setting. In addition to live programs, technology enabled distance learning, online courses, and other enduring materials may also be proposed.

Applications due October 3, 2016

  Independent Grants for Learning & Change (IGL&C) - Geriatric Oncology Needs Assessment | Pfizer, Inc. (Deadline: 10/12/16)

Independent Grants for Learning & Change (IGL&C) – Geriatric Oncology Needs Assessment | Pfizer, Inc.

The mission of Pfizer Independent Grants for Learning & Change (IGL&C) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. "Independent" means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

Through this CGA Pfizer encourages organizations to submit grant requests that, if funded, will support education in a specific disease state, therapeutic area, or broader area of educational need.

It is Pfizer's intent to provide an independent grant to an organization or organizations who will conduct a thorough educational needs assessment in the area of geriatric oncology. With a growing population of older adults with cancer (greater than or equal to 70 years old), there is a growing educational need in terms of how to properly assess these individuals and make treatment decisions in line with their individual needs. Health care providers need to be able to adjust their practice for older adult patients, taking into consideration factors such as: risk of falling, muscle weakness, fatigue, cognitive deficits, and declining immune system.

The needs assessment should be focused on oncologists at academic medical centers and/or community cancer centers and clinics. Other multi-disciplinary health-care professionals and care-team members should also be included. Pfizer's intent is for the results of the needs assessment to be shared with the entire medical community in order to enhance future medical education programs and close gaps in the quality of care for older adults with cancer. In addition, the results will be used to inform educational budget planning and future Call for Grant Applications (CGAs) and Request for Proposals (RFPs).

Applications due October 12, 2016

  American Cancer Society
  Pilot and Exploratory Projects in Palliative Care of Cancer Patients and Their Families | American Cancer Society (Deadline: 10/17/16)

Pilot and Exploratory Projects in Palliative Care of Cancer Patients and Their Families | American Cancer Society

This RFA provides funding for investigators performing pilot and exploratory research studies whose purpose is to test interventions, develop research methodologies, and explore novel areas of research in palliative care of cancer patients and their families. A condition of funding is a clearly defined plan as to how the investigator will use the results of the project to develop larger, extramurally funded research projects.

This RFA is limited to applications that focus on palliative care research projects for seriously ill cancer patients and their families in three specific areas:

  1. Exploring the relationship of pain and other distressing symptoms on quality and quantity of life, independence, function, and disability and developing interventions directed at their treatment in patients with advanced and chronic illnesses;
     
  2. Studying methods of improving communication between adults living with serious illness, their families and their health care providers;
     
  3. Evaluating models and systems of care for patients living with advanced illness and their families.

Applications due October 17, 2016

  Request for Proposals: Established Investigator Awards | Melanoma Research Alliance (Deadline: 10/21/16)

Request for Proposals: Established Investigator Awards | Melanoma Research Alliance

The MRA is pleased to announce a Request for Proposals (RFP) for high-impact translational research that has the potential to lead to near-term clinical application in melanoma prevention, detection, diagnosis, staging, and treatment.

MRA welcomes proposals in the following areas:

Prevention
Elucidation of environmental, epidemiological, and biological factors in melanoma genesis that lead to prevention strategies.

Detection, Diagnosis, and Staging
Development of targeted screening methods and identification and validation of diagnostic and prognostic biomarkers.

Treatment
Projects emphasizing the translation of scientific findings to new treatments for patients with melanoma. Examples include but are not limited to studies of melanoma immunotherapy, therapeutic applications based on molecular mechanisms involved in melanoma formation and/or progression, combination therapies, and development of novel biomarkers of response to therapy.

Special Emphasis Areas

For the 2016-2017 cycle, MRA seeks proposals in the following areas , which are focused on current unmet clinical needs in melanoma. These areas are of particular interest and will receive special consideration. These can include pre-clinical, clinical, and/or correlative scientific studies:

  1. Addressing treatment failures or difficult-to-treat disease, which may include rare melanoma subtypes or metastatic brain disease, by undertaking studies leading to new targets and/or rational treatment approaches
     
  2. Informing logical and optimal combination therapies, therapeutic sequences, or treatment regimens, including defining dose or duration of targeted and /or immunotherapies
     
  3. Developing markers of response, resistance, or risk of recurrence or death i n early stage disease to improve clinical decision – making and speed the development of new melanoma therapies in the neoadjuvant, adjuvant, or advanced setting
     
  4. Identifying new targets, treatments, or biomarkers via the study of exceptional responders/non-responders and/or leveraging data (e.g. clinical, genomics, and immunologic) from within and outside melanoma.

Applications due October 21, 2016

  Request for Proposals: Established Investigator Academic-Industry Partnership Awards | Melanoma Research Alliance (Deadline: 10/21/16)

Request for Proposals: Established Investigator Academic-Industry Partnership Awards | Melanoma Research Alliance

The MRA is soliciting proposals that address the gap in translational science, i.e., turning scientific discoveries into tools and/or treatments for high risk individuals and melanoma patients. Successful proposals will offer the potential for translational development that could lead to high impact near-term clinical application in melanoma detection, prevention, diagnosis, staging, or treatment.

The Established Investigator Awards are designed to facilitate progress via interactions between the academic and industrial research sectors, and will be co-funded by MRA and an industrial collaborator whose involvement is essential to the project.

It is the responsibility of the academic scientist to find an industrial partner whose involvement and collaboration will be vital to conducting the research project, or vice versa.

MRA welcomes proposals in the following areas:

Prevention
Elucidation of environmental, epidemiological and biological factors in melanoma carcinogenesis.

Diagnosis and Staging
Development of targeted screening methods and identification and validation of diagnostic and prognostic biomarkers.

Treatment
Projects emphasizing the translation of scientific findings to new treatments for patients with melanoma are solicited. Examples include, but are not limited to, studies of melanoma immunotherapy, therapeutic applications based on molecular mechanisms involved in melanoma formation and/or progression, combination therapies, and development of novel biomarkers of response to therapy.

Special Emphasis Areas for the 2016–2017 Cycle

MRA seeks proposals in the following areas, which are focused on current unmet clinical needs in melanoma. These areas are of particular interest and will receive special consideration. These can include pre-clinical, clinical, and/or correlative scientific studies:

  1. Addressing treatment failures or difficult-to-treat disease, which may include rare melanoma subtypes or metastatic brain disease, by undertaking studies leading to new targets and/or rational treatment approaches
     
  2. Informing logical and optimal combination therapies, therapeutic sequences, or treatment regimens, including defining dose or duration of targeted and /or immunotherapies
     
  3. Developing markers of response, resistance, or risk of recurrence or death in early stage disease to improve clinical decision-making and speed the development of new melanoma therapies in the neoadjuvant, adjuvant, or advanced setting
     
  4. Identifying new targets, treatments, or biomarkers via the study of exceptional responders/non-responders and/or leveraging data (e.g. clinical, genomics , and immunologic) from within and outside melanoma

Applications due October 21, 2016

  Request for Proposals: Young Investigator Awards | Melanoma Research Alliance (Deadline: 10/21/16)

Request for Proposals: Young Investigator Awards | Melanoma Research Alliance

This program aims to attract early career scientists with novel ideas into melanoma research, thereby recruiting and supporting the next generation of melanoma researchers.

MRA welcomes proposals in the following areas:

Prevention
Elucidation of environmental, epidemiological, and biological factors in melanoma carcinogenesis.

Detection, Diagnosis, and Staging
Development of targeted screening methods and identification and validation of diagnostic and prognostic biomarkers.

Treatment
Projects emphasizing the translation of scientific findings to new treatments for patients with melanoma. Examples include but are not limited to studies of melanoma immunotherapy, therapeutic applications based on molecular mechanisms involved in melanoma formation and/or progression, combination therapies, and development of novel biomarkers of response to therapy.

Special Emphasis Areas

For the 2015 - 2016 cycle, MRA seeks proposals in the following areas, which are focused on current unmet clinical needs in melanoma. These areas are of particular interest and will receive special consideration. These can include pre-clinical, clinical, and/or correlative scientific studies:

  1. Undertaking studies that define logical and optimal combination therapies, therapeutic sequences, or treatment regimens to improve outcomes and curtail resistance to current and emerging therapies.
     
  2. Identifying biomarkers of risk of recurrence or death in early stage disease for improved clinical management and to speed the development of adjuvant therapies as well as markers of response/resistance to approved and investigational therapies which may include tumor, microenvironment, immunological, imaging or circulating biomarkers.
     
  3. Research leading to improvements in difficult-to-treat disease or treatment failures, including melanoma subtypes (e.g., acral and uveal melanomas) and metastatic brain disease, by identifying new targets and/or treatment approaches for recalcitrant molecular targets.
     
  4. Improving the understanding of the biological basis for melanoma formation, such as risk factors and the interaction of risk and the environment, in order to develop better prevention and early detection strategies.

Applications due October 21, 2016

  Specialized Center of Research Program | Leukemia & Lymphoma Society (Deadline: 3/1/17)

Specialized Center of Research Program | Leukemia & Lymphoma Society

LLS's Specialized Center of Research (SCOR) grant program is intended to bring together established investigators from one or several institutions to develop a focused research program, foster new interactions and cooperation, and enhance interdisciplinary research among the participants. The overall goal of this mechanism is to enhance the development of innovative strategies for the treatment, diagnosis or prevention of hematological malignancies. Strategies that move discoveries from the bench to the clinic are of high importance as are integrated translational projects.

Applications due March 1, 2017

Medical College of Wisconsin
8701 Watertown Plank Road
Milwaukee, WI 53226
(414) 955-8296
Directions & Maps
© 2016

Page Updated 08/25/2016
Top